Clinical Trials Logo

Lesch-Nyhan Disease clinical trials

View clinical trials related to Lesch-Nyhan Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01065558 Completed - Lesch-Nyhan Disease Clinical Trials

Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its family of receptors (i.e, the D1 family). LND is a very rare genetic disease. The sponsor is doing this study to find out what side effects ecopipam causes in LND patients, and whether ecopipam may be able to relieve the self-injurious behaviors seen in these patients.